Phase 1/2 Study of EB-NK-301 (Allogeneic TROP2-CAR NK Cells) in Advanced TROP2-Expressing Solid Tumors

Inclusion Criteria:

* Age 18 to 75 years at the time of informed consent.
* Histologically or cytologically confirmed advanced or metastatic solid tumor with documented TROP2 expression (per local testing or central confirmation).
* Disease progression on, intolerance to, or ineligibility for available standard therapy.
* At least one measurable lesion per RECIST 1.1.
* ECOG performance status 0 to 1.
* Adequate organ function (hematologic, renal, hepatic) within protocol-defined limits.
* Life expectancy ≥ 12 weeks.
* Willingness to use effective contraception during study participation and for a protocol-defined period after last infusion (if of childbearing potential).
* Ability to understand and willingness to sign written informed consent.

Exclusion Criteria:

* Active central nervous system (CNS) metastases or leptomeningeal disease (unless treated and clinically stable for ≥ 4 weeks).
* Prior allogeneic hematopoietic stem cell transplant or solid organ transplant.
* Uncontrolled active infection, including uncontrolled hepatitis B, hepatitis C, or HIV infection.
* Active autoimmune disease requiring systemic immunosuppression.
* Clinically significant cardiovascular disease (e.g., recent myocardial infarction or stroke within 6 months, uncontrolled arrhythmia).
* Receipt of another investigational agent within 2 weeks (or 5 half-lives, whichever is longer) prior to lymphodepleting chemotherapy.
* Prior gene-modified cellular therapy within 3 months prior to enrollment.
* Systemic corticosteroid therapy \> 10 mg/day prednisone equivalent within 7 days prior to lymphodepletion (excluding physiologic replacement).
* Pregnant or breastfeeding.